Stephanie Griff MacAusland, J.D., M.D.
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Palpation | 1 | 2008 | 166 | 0.310 |
Why?
|
| Cicatrix | 1 | 2008 | 799 | 0.210 |
Why?
|
| Carcinoma in Situ | 1 | 2007 | 791 | 0.200 |
Why?
|
| Carcinoma, Ductal, Breast | 1 | 2007 | 1092 | 0.170 |
Why?
|
| Radiotherapy Planning, Computer-Assisted | 1 | 2008 | 1680 | 0.170 |
Why?
|
| Neoplasms, Second Primary | 1 | 2007 | 1062 | 0.170 |
Why?
|
| Cisplatin | 1 | 2021 | 1661 | 0.120 |
Why?
|
| Iridium | 1 | 2011 | 30 | 0.100 |
Why?
|
| Mastectomy, Segmental | 2 | 2021 | 961 | 0.090 |
Why?
|
| Radioisotopes | 1 | 2011 | 516 | 0.080 |
Why?
|
| Breast | 2 | 2009 | 1976 | 0.080 |
Why?
|
| Subcutaneous Tissue | 1 | 2009 | 132 | 0.080 |
Why?
|
| Electrons | 1 | 2008 | 266 | 0.070 |
Why?
|
| Cryotherapy | 1 | 2008 | 160 | 0.070 |
Why?
|
| Mastectomy | 2 | 2021 | 1852 | 0.070 |
Why?
|
| Vagina | 1 | 2011 | 845 | 0.060 |
Why?
|
| Radiotherapy, Conformal | 1 | 2009 | 549 | 0.060 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2008 | 20762 | 0.060 |
Why?
|
| Breast Neoplasms | 2 | 2009 | 21156 | 0.060 |
Why?
|
| Radiation Dosage | 2 | 2011 | 1973 | 0.060 |
Why?
|
| Brachytherapy | 1 | 2011 | 1227 | 0.060 |
Why?
|
| Organ Size | 1 | 2008 | 2268 | 0.050 |
Why?
|
| Radiotherapy, Adjuvant | 1 | 2008 | 1794 | 0.050 |
Why?
|
| Tumor Burden | 1 | 2008 | 1909 | 0.050 |
Why?
|
| Chi-Square Distribution | 1 | 2008 | 3438 | 0.050 |
Why?
|
| Health Status Indicators | 1 | 2007 | 971 | 0.050 |
Why?
|
| Endometrial Neoplasms | 1 | 2011 | 1382 | 0.050 |
Why?
|
| Radiotherapy, Intensity-Modulated | 1 | 2008 | 811 | 0.050 |
Why?
|
| Radiation Injuries | 1 | 2009 | 1205 | 0.050 |
Why?
|
| Analysis of Variance | 1 | 2008 | 6242 | 0.040 |
Why?
|
| Maximum Tolerated Dose | 1 | 2021 | 890 | 0.040 |
Why?
|
| Mammography | 1 | 2008 | 2436 | 0.040 |
Why?
|
| Aged | 5 | 2021 | 171520 | 0.020 |
Why?
|
| Age Factors | 1 | 2007 | 18478 | 0.020 |
Why?
|
| Adenocarcinoma | 1 | 2008 | 6400 | 0.020 |
Why?
|
| Middle Aged | 5 | 2021 | 223418 | 0.020 |
Why?
|
| Combined Modality Therapy | 1 | 2021 | 8559 | 0.020 |
Why?
|
| Adult | 3 | 2021 | 223542 | 0.020 |
Why?
|
| Prognosis | 1 | 2007 | 30028 | 0.020 |
Why?
|
| Rectum | 1 | 2011 | 902 | 0.020 |
Why?
|
| Neoplasm Staging | 1 | 2021 | 11249 | 0.020 |
Why?
|
| Aged, 80 and over | 2 | 2009 | 59680 | 0.020 |
Why?
|
| Female | 5 | 2021 | 396943 | 0.020 |
Why?
|
| Prostatic Neoplasms | 1 | 2008 | 11206 | 0.020 |
Why?
|
| Urinary Bladder | 1 | 2011 | 1160 | 0.020 |
Why?
|
| Radiotherapy Dosage | 1 | 2009 | 2925 | 0.010 |
Why?
|
| Fibrosis | 1 | 2009 | 2076 | 0.010 |
Why?
|
| Salvage Therapy | 1 | 2008 | 1277 | 0.010 |
Why?
|
| Temperature | 1 | 2008 | 2237 | 0.010 |
Why?
|
| Humans | 6 | 2021 | 768451 | 0.010 |
Why?
|
| Regression Analysis | 1 | 2009 | 6353 | 0.010 |
Why?
|
| Retrospective Studies | 1 | 2007 | 81834 | 0.010 |
Why?
|
| Prostate-Specific Antigen | 1 | 2008 | 2483 | 0.010 |
Why?
|
| Prospective Studies | 1 | 2021 | 54914 | 0.010 |
Why?
|
| Biopsy | 1 | 2008 | 6816 | 0.010 |
Why?
|
| Risk | 1 | 2008 | 9642 | 0.010 |
Why?
|
| Young Adult | 1 | 2021 | 60045 | 0.010 |
Why?
|
| Follow-Up Studies | 1 | 2009 | 39430 | 0.000 |
Why?
|
| Treatment Outcome | 1 | 2008 | 65409 | 0.000 |
Why?
|
| Male | 1 | 2008 | 364781 | 0.000 |
Why?
|